Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
-
ThromboGenics NV : ThromboGenics Successfully Introduces New 'Already-Diluted' Formulation of JETREA® (ocriplasmin) in the US
-
ThromboGenics NV : ThromboGenics Presenting THR-687 Preclinical Data at European Association for Vision and Eye Research (EVER) Meeting
-
ThromboGenics NV : ThromboGenics Regains Global Rights to JETREA® (ocriplasmin)
-
ThromboGenics Business Update - H1 2017
-
ThromboGenics Business Update - FY 2016
-
ThromboGenics Business Update - Q3 2016
-
Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago
-
ThromboGenics Presenting New Ophthalmic Research Data
-
ThromboGenics Business Update - Q1 2016
-
New Ocriplasmin Research Findings Presented
-
ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
-
ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
-
ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
-
ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retino
-
ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
-
ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
-
ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
-
ThromboGenics Business Update - Q3 2015
-
Baron Philippe Vlerick increases shareholding in ThromboGenics NV to 6.4%
-
ThromboGenics Business Update H1 2015
-
ThromboGenics Q1 2015 Business Update
-
ThromboGenics Starts Evaluating JETREA(r) for the Treatment of Retinal Vein Occlusion (RVO)
-
ThromboGenics and VIB launch New Oncology Company
-
OASIS Study Clarification with regard to number of ERM Patients recruited
-
ThromboGenics Announces Positive Topline Results from OASIS Study
-
ThromboGenics' JETREA(r) Gains Approval in Brazil
-
ThromboGenics Full Year 2014 Business Update
-
ThromboGenics Appoints Dr Joseph Markoff as Scientific Advisor
